Major Stocks Including BlackBerry, FedEx, and Nike Decline in Friday's Pre-Market Trading

Written by Emily J. Thompson, Senior Investment Analyst

FDMT-1.23%

SRTA-3.75%

NKE-1.26%

Source: Benzinga

Updated: Dec 19 2025

0mins

Source: Benzinga

U.S. Stock Futures: U.S. stock futures are mostly higher, with Nasdaq 100 futures gaining around 100 points on Friday.
BlackBerry Earnings Report: BlackBerry Ltd reported third-quarter revenue of $141.8 million, exceeding analyst expectations, but shares fell 4.6% in pre-market trading.
Other Stocks Declining: Several stocks, including Aimei Health Technology and Nike Inc, experienced significant declines in pre-market trading despite some reporting better-than-expected earnings.
Market Overview: The overall market sentiment is cautious, with various stocks showing downward trends following recent earnings reports and inflation data.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like FDMT with instant alerts to capture every critical market movement.

FDMT

$8.86+Infinity%1D

Analyst Views on FDMT

Wall Street analysts forecast FDMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FDMT is 29.40 USD with a low forecast of 17.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Analyst Rating

5 Buy

0 Hold

1 Sell

Moderate Buy

Current: 8.970

Low

17.00

Averages

29.40

High

38.00

Current: 8.970

Low

17.00

Averages

29.40

High

38.00

Barclays

initiated

$33

2026-01-27

New

Reason

Barclays

Price Target

$33

AI Analysis

2026-01-27

New

initiated

Reason

Barclays assumed coverage of 4D Molecular with an Overweight rating and $33 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."

RBC Capital

Lisa Walter

Outperform

maintain

$26 -> $32

2025-11-11

Reason

RBC Capital

Lisa Walter

Price Target

$26 -> $32

2025-11-11

maintain

Outperform

Reason

RBC Capital analyst Lisa Walter raised the firm's price target on 4D Molecular to $32 from $26 and keeps an Outperform rating on the shares after its Q3 results. The company's current cash position of $372M plus additional funds from the recent APAC deal with Otsuka and capital raise should extend the runway by 6 months into the second half of FY28 and fund both wAMD and DME pivotals, the analyst tells investors in a research note, adding that the recent funding "adds some cushion to the runway".

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FDMT

Unlock Now

About FDMT

4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for FDMT?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy FDMT?

Get Started Free

Top News

4D Molecular Therapeutics Grants 23,600 RSUs to New Employees

Jan 17 2026Globenewswire

Employee Incentive Program: On January 13, 2026, 4D Molecular Therapeutics' compensation committee granted 23,600 Restricted Stock Units (RSUs) to four new non-executive employees, aimed at attracting talent and enhancing team stability.
Equity Grant Context: The RSUs were awarded under the 2025 Employment Inducement Award Plan, approved by the board in February 2025, complying with Nasdaq Rule 5635(c)(4), reflecting the company's commitment to talent acquisition.
Product Development Progress: The company's lead product, 4D-150, is currently in Phase 3 trials, designed to provide multi-year sustained delivery of anti-VEGF through a single safe intravitreal injection, significantly reducing the treatment burden associated with current methods, showcasing transformative potential.
Gene Therapy Innovation: The second candidate, 4D-710, is the first known genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients, demonstrating the company's innovative capabilities and market potential in the therapeutic landscape.